Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
about
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaProteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI.Proteasome inhibitors in glioblastomaBasic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome.Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosisTargeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibProteasome inhibitors in the treatment of multiple myelomaEmerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseasesCytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaUnderstanding proteasome assembly and regulation: importance to cardiovascular medicine.Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidanceMolecular mechanisms of acquired proteasome inhibitor resistance.Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.Characterization of bortezomib-adapted I-45 mesothelioma cellsImmune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.(Immuno)proteasomes as therapeutic target in acute leukemia.Proteasome inhibitors in cancer therapy.Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
P2860
Q28533736-5CF8416A-B625-4A3C-9D5F-538ED48AAED1Q30479870-B39081C4-C104-4954-A354-990285C8B2CEQ33598931-0C4826D1-F5CC-4989-A247-722D9A463631Q33768364-775374A4-0DCC-41B2-AB4E-81D9F9559654Q34179925-FFAE360A-76EA-4020-83EE-718A10C8C661Q34195083-08F9DE15-EF52-48E0-982C-89D88A936701Q34227679-98AF726F-086D-4165-9576-B376B4E3B267Q34317307-3305D2D4-BF6A-45F7-A2B2-09712A0C0E76Q34611676-D56FE4A3-4045-4E2F-9394-C1CA343DF24FQ35009005-C8F01C01-8E95-4433-B07A-8C651FC0D1EDQ35904520-C5434380-D666-4DDB-8545-1ABC20A4D0E1Q36141927-F85056E6-362B-4876-8135-AACCFB0A2CCCQ36333522-5A436161-60CE-454E-9758-84921888370FQ36372909-0DEC1E41-F18E-41D7-813F-E6FD65830C5EQ36444233-BCD7D443-2761-4F00-8A42-B57184C027BDQ36740475-FF968AE5-DE69-4D30-A06D-0D1550E81754Q36807352-F901AAB2-8257-4724-852D-6DA7E7B752CDQ37318005-33ECBC17-CE1A-44F2-A271-83E2F75CC26DQ37688848-1C21C60D-4A14-4857-9EAC-95FBF7A41FF7Q38088360-4C633691-2CE8-4773-89B9-1880192F0FCBQ38739048-114EB7FB-CD8D-45C8-82E5-B92ACE2E33D3Q39278628-D9F85B53-B95D-4BFE-86C0-85C5FE61ECFFQ39569161-B3407C36-E9C7-434A-B362-8D2738BD4020Q39702665-B6831512-18A4-4F9B-A183-E7A449C0050CQ41592583-8B672F38-D6DF-463E-9680-085283FA1B87Q41607725-E1DF1AE1-2C1C-467C-A8EB-49487B4BCE54Q43195076-9CA045E4-69D2-478B-95B3-CBCF2A3E1368Q43288668-6F9B7FC4-4234-4D6A-9B25-94F5750B0264Q44236379-4C0417CD-7926-4E16-BE1C-C72BF7AB390AQ47131929-D6CB9556-ADAE-43AF-9BEA-1ABEF8D0BF66Q53752929-5E25281D-E9CF-4412-89A4-CBC5C1F976A7Q55027177-F34CBFA3-3E7C-41B7-B2D4-8C09BD1F7943
P2860
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@ast
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@en
type
label
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@ast
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@en
prefLabel
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@ast
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@en
P2093
P356
P1476
Increased expression and alter ...... ion of Burkitt lymphoma cells.
@en
P2093
Carsten Berges
Cord Naujokat
Dominik Fuchs
Volker Daniel
P2860
P304
P356
10.1002/JCB.21405
P577
2008-01-01T00:00:00Z